CRISPR Therapeutics AG Aktie News

Is it time to reload your portfolio with some new picks? That's easier said than done right now.

If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line.

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

CRSP's innovative pipeline shines, but the biotech does face regulatory risks and fierce competition.

Crispr Therapeutics AG is transitioning to a commercial company, with CASGEVY's rollout and a robust pipeline in cardiovascular, autoimmune, and oncology driving long-term potential. The cardiovascular franchise, especially CTX-310 and CTX-320, offers blockbuster potential with best-in-class efficacy and a compelling one-time treatment value proposition. Recent partnerships, like Sirius Therape...

Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end.

CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon. Thank you, everyone, for joining us.

CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started.